Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSĀ® platform to develop in vivo gene editing ther...
What potential impact could these results and updates have on the stockās valuation and price movement?
Are there any competitive threats or market dynamics highlighted that could affect Precision BioSciences' positioning?
What is the status of the ARCUSĀ® platform development and any upcoming milestones or trials?
19 days ago